We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Evaluating the efficacy and safety of single-agent etoposide intra-CSF chemotherapy in children and young people with relapsed/refractory central nervous system tumours.
- Authors
Butler, Anna; Meijer, Lisethe; Liu, Jo-Fen; Chohan, Manjit; Jalloh, Ibrahim; Macarthur, Donald; Parr, Margaret; Wilne, Sophie; Wilson, Shaun; Walker, David; Grundy, Richard; Dandapani, Madhumita
- Abstract
Purpose: The aim of the project was to evaluate intra-CSF etoposide administration in a palliative setting for children and young people with relapsed/refractory central nervous system (CNS) tumours, with the primary endpoints being overall survival and progression-free survival time. A safety endpoint was to assess the side effect profile and complications of intra-CSF etoposide. Methods: Thirty-five patients under the age of 30 years (median age: 5.33 years) were enrolled onto the project. The cross-centre study was a service evaluation, with a data collection spreadsheet designed in Nottingham and completed by both Nottingham and Oxford centres. Data was analysed using SPSS, assessing the overall survival and progression-free survival times, as well as the 6-month and 1-year survival rates. Results: The median overall survival and progression-free survival times were 10.97 and 5.91 months, respectively. The 6-month and 1-year overall survival rates were 67% and 48%, and the progression-free survival rates were 50% and 22%. Age at the start of intra-CSF therapy was significantly associated with overall survival (P = 0.046), with the 6 + age group having improved overall survival. Treatment type was significantly associated with overall survival (P = 0.012), with etoposide intra-CSF treatment being associated with improved overall survival. Treatment duration was significantly associated with both overall survival (P < 0.001) and progression-free survival (P < 0.001). Conclusion: Intra-CSF etoposide treatment has shown to increase both overall and progression-free survival significantly, whilst having few side effects and maintaining a good quality of life for patients, reflecting it as a beneficial therapy in the palliative setting.
- Subjects
NOTTINGHAM (England); YOUNG adults; CENTRAL nervous system; PROGRESSION-free survival; SURVIVAL analysis (Biometry); OVERALL survival
- Publication
Child's Nervous System, 2023, Vol 39, Issue 6, p1537
- ISSN
0256-7040
- Publication type
Article
- DOI
10.1007/s00381-023-05872-w